Thermo Fisher Scientific Inc (NYSE:TMO), a provider of technology, pharmaceutical and biotechnology services, announced on Wednesday that it has entered into a strategic collaboration with drug delivery company SHL Medical, alongside an expansion of its Ridgefield, NJ site, to deliver fully integrated drug-device combination solutions. The Ridgefield facility will combine sterile fill-finish, autoinjector final assembly and commercial packaging in a single US location.

The move responds to growing demand for self-administered injectable therapies across autoimmune, inflammatory, and chronic diseases. Thermo Fisher is expanding pre-filled syringe fill-finish and device assembly at Ridgefield, while SHL Medical's Molly autoinjector platform will be integrated into Thermo Fisher's sterile manufacturing network, providing end-to-end support from drug product to finished device.

Acquired from Sanofi in September 2025, the Ridgefield site is being developed as a North American hub for integrated manufacturing, enhancing domestic capacity and streamlining supply chains for pharmaceutical and biotechnology customers. Under the non-exclusive collaboration, both companies will provide device assembly, packaging, and distribution for the Molly autoinjector.

Ridgefield complements Thermo Fisher's global manufacturing network, including sites in Allentown, PA, Horsham, UK, and upcoming capacity in Greenville, NC. Investments across its steriles network, including Ferentino, Italy and the Asia-Pacific region, aim to support scalable development and commercialisation of drug-device therapies worldwide.